Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI guided transurethral high intensity ultrasound ablation of the prostateStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
MT656 Paige Prostate AI system for the detection of prostate cancerStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Relugolix for treating hormone-sensitive prostate cancer [ID6187]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Stockholm3 blood test for prostate cancer, (MT734),Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC